Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jul 9, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has hired Gary King to fill the new position of executive VP of international operations, a job in which he will oversee expansion into Europe and other international markets. He will be responsible for sales and marketing, regulatory approval, and reimbursement, and he will execute and develop the firm's strategies on "a country-by-country" basis. King most recently was CEO of biomarker and diagnostics company AverDx, and he also was VP of international operations at Biosite.

Qiagen has appointed Ellen Sheets to serve as chief medical officer. Sheets will develop the company's biomarker and cancer diagnostics strategies. She has been VP of clinical affairs and CMO for Hologic, and joins Qiagen from Predictive Biosciences, where she was general manager and CMO. Sheets also was an associate professor at Harvard Medical School.

Ingen Biosciences has named Karine Mignon-Godefroy to lead the company's research and development efforts. As director of R&D, Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens for detecting infectious diseases found in prosthetic replacements and to develop IVD kits for clinical use.

She formerly was director of international projects in Bio-Rad's Blood Virus division, and she was R&D manager at BMD, where she developed reagents based on Luminex technologies. She also was a group leader at Chemunex, a firm that focuses on detecting microbial contamination.

Douglas White has become CEO of OpGen, taking over from Evan Jones, who had held the position on an interim basis and will remain on OpGen's board of directors. Prior to joining the firm, White was executive vice president and general manager for the diagnostics division of BG Medicine. Before that, he was chairman of the Americas management council and senior vice president of sales and marketing for the Americas at Qiagen.

Jonathan Dorfan has been named president-elect of the Okinawa Institute of Science and Technology Graduate University. Dorfan is former director of the Department of Energy's Stanford Linear Accelerator Center, now named SLAC National Accelerator Laboratory. When OIST receives its accreditation, which is expected in late 2011,and formally becomes a university, he will become the university's first president and CEO of the OIST School Corporation.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.